Time called on Pfizer–AstraZeneca deal


Pfizer’s pursuit of a pharmaceutical megamerger with AstraZeneca (AZ) has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK’s takeover rules.

The City Code on Takeovers and Mergers allows Pfizer to make a new approach to AZ after a six month cooling off period, or AZ can invite Pfizer to negotiate after three months. Given the Anglo-Swedish firm’s steadfast refusal to entertain Pfizer’s advances, the latter option seems unlikely. ‘We welcome the opportunity to continue building on the momentum we have already demonstrated as an independent company,’ AZ’s chairman Leif Johansson said in a statement after the withdrawal.

Pfizer, in its turn, is leaving the door open. ‘We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us’ said chief executive Ian Read in the withdrawal statement. The value and attactiveness of any new offer will depend strongly on how well AZ lives up to predictions about forthcoming drugs made by the board to justify its refusal of this deal. 


Related Content

Pfizer and Allergan agree mega-merger

27 November 2015 Business

news image

$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland

Pfizer presses hard for AstraZeneca deal

14 May 2014 Business

news image

Executives face down international controversy over tax schemes and previous post-merger record

Most Commented

Electric choc treatment promises lower fat chocolate

22 June 2016 Research

news image

Problem of reduced fat chocolate gumming up factories’ pipelines overcome

Behind closed doors: How to win the Nobel prize

7 October 2015 Comments

news image

Bengt Norden addresses the myths and rumours surrounding the world's most prestigious science prize